Drug and Therapeutics Bulletin 1994;32:25-27; doi:10.1136/dtb.1994.32425
Copyright © 1994 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Fluticasone propionate for asthma prophylaxis

Relevant BNF section: 3.2

Inhaled corticosteroids have an essential role in the management of many patients with asthma,1 improving control and reducing the need for oral corticosteroids. Used in conventional dosage inhaled corticosteroids are very safe; in high dosage systemic effects are more evident. Fluticasone propionate (Flixotide - Allen & Hanburys), a new inhalation corticosteroid, is promoted as being more potent than conventional preparations (beclomethasone dipropionate and budesonide) and less likely to cause systemic effects. Is this claim justified and what is the place of fluticasone propionate in asthma prophylaxis?






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1994 BMJ Publishing Group Ltd.